(Q46419102)

22 December 2017

title

Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression (English)

1 reference

22 December 2017

1 reference

5

Reynolds CP

1 reference

22 December 2017

author name string

Anderson CP

1

1 reference

22 December 2017

Keshelava N

2

1 reference

22 December 2017

Satake N

3

1 reference

22 December 2017

Meek WH

4

1 reference

22 December 2017

publication date

1 December 2000

1 reference

22 December 2017

published in

Pediatric Blood Cancer

1 reference

22 December 2017

volume

35

1 reference

22 December 2017

issue

6

1 reference

22 December 2017

page(s)

659-662

1 reference

22 December 2017

Current aspects of biology, risk assessment, and treatment of neuroblastoma

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C659%3A%3AAID-MPO38%3E3.0.CO%3B2-4

Biology and treatment of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C659%3A%3AAID-MPO38%3E3.0.CO%3B2-4

Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C659%3A%3AAID-MPO38%3E3.0.CO%3B2-4

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C659%3A%3AAID-MPO38%3E3.0.CO%3B2-4

Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C659%3A%3AAID-MPO38%3E3.0.CO%3B2-4

Drug resistance in human neuroblastoma cell lines correlates with clinical therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C659%3A%3AAID-MPO38%3E3.0.CO%3B2-4

p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C659%3A%3AAID-MPO38%3E3.0.CO%3B2-4

Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C659%3A%3AAID-MPO38%3E3.0.CO%3B2-4

In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C659%3A%3AAID-MPO38%3E3.0.CO%3B2-4

Depletion of glutathione by buthionine sulfoxine is cytotoxic for human neuroblastoma cell lines via apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C659%3A%3AAID-MPO38%3E3.0.CO%3B2-4

Buthionine sulphoximine alone and in combination with melphalan (L-PAM) is highly cytotoxic for human neuroblastoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C659%3A%3AAID-MPO38%3E3.0.CO%3B2-4

Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C659%3A%3AAID-MPO38%3E3.0.CO%3B2-4

A fluorescence digital image microscopy system for quantifying relative cell numbers in tissue culture plates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C659%3A%3AAID-MPO38%3E3.0.CO%3B2-4

Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C659%3A%3AAID-MPO38%3E3.0.CO%3B2-4

Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C659%3A%3AAID-MPO38%3E3.0.CO%3B2-4

Depletion of Glutathione in Normal and Malignant Human Cells In Vivo by Buthionine Sulfoximine: Clinical and Biochemical Results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C659%3A%3AAID-MPO38%3E3.0.CO%3B2-4

Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C659%3A%3AAID-MPO38%3E3.0.CO%3B2-4

Pharmacokinetics of high dose melphalan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C659%3A%3AAID-MPO38%3E3.0.CO%3B2-4

10.1002/1096-911X(20001201)35:6<659::AID-MPO38>3.0.CO;2-4

21 January 2018

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017